Relapse prevention in reflux oesophagitis with regard to Helicobacter pylori status: A double-blind, randomized, multicentre trial to compare the efficacy of pantoprazole versus ranitidine

European Journal of Gastroenterology and Hepatology

Volumn 13, Issue 7, 2001, Pages 811-817

  Adamek, Romuald J ^a   Behrendt, Jutta ^b   Wenzel, Caroline ^b  

^a StVinzenz Hospital   (Germany)

^b Schwarz Pharma AG   (Germany)

Author keywords

Eradication therapy; Helicobacter pylori; Pantoprazole; Ranitidine; Reflux oesophagitis

Indexed keywords

CLARITHROMYCIN; METRONIDAZOLE; PANTOPRAZOLE; RANITIDINE;

ADULT; ARTICLE; BACTERIAL INFECTION; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ERADICATION THERAPY; FEMALE; HELICOBACTER PYLORI; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REFLUX ESOPHAGITIS; TREATMENT OUTCOME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; BENZIMIDAZOLES; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; ESOPHAGITIS, PEPTIC; FEMALE; H(+)-K(+)-EXCHANGING ATPASE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; OMEPRAZOLE; RANITIDINE; RECURRENCE; SULFOXIDES;

EID: 0034953767     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/00042737-200107000-00009     Document Type: Article

References (21)

1. Berges W, Wienbeck M. Moderne Therapie der Refluxoesophagitis (modern therapy of reflux oesophagitis). Med Klin 1987; 82: 26-29 [German].
2. Lind T, Cederberg C, Ekenved G, Olbe L. Inhibition of basal and betazole- and sham-feeding-induced acid secretion by omeprazole in man. Scand J Gastroenterol 1986; 21: 1004-1010.
3. Tucker GT. The interaction of proton pump inhibitors with cytochromes P450. Aliment Pharmacol Ther 1994; 8 (suppl 1): 33-38.
4. Kromer W, Postius S, Riedel R, Simon WA, Hanauer G, Brand U. et al. BY 1023/SK&F 96022 INN pantoprazole, a novel gastric proton pump inhibitor, potently inhibits acid secretion but lacks relevant cytochrome P450 interactions. J Pharmacol Exp Ther 1990; 254: 129-135.
5. Koop H, Schepp H, Dammann HG, Schneider A, Luemann R, Classen M. Comparative trial of pantoprazole and ranitidine in the treatment of reflux oesophagitis: Results of a German multicentre study. J Clin Gastroenterol 1995; 20: 192-195.
6. Dammann HG, von Kleist DH. Efficacy and tolerability of pantoprazole versus ranitidine and famotidine in patients with gastro-oesophageal reflux disease: multicentre, open, randomised, controlled studies. Intern Clin Pract Ser 1997; 15: 23-29.
7. Duvnjak M, Simicevic VN, Supanc V, Troskot B, Pavic T, Hrabar D. Efficacy of pantoprazole in gastroesophageal reflux disease: A comparison with ranitidine. Digestion 1998; 59 (suppl 3): 583-586.
8. Gallo S, Dibildox M, Moguel A, Di Silvio M, Rodriguez F, Almaguer I. et al. Superioridad clinica del pantoprazol sobre la ranitidina en la curacion de la esofagitis por reflujo grado II y III. Estudio prospectivo, doble ciego, doble placebo. Experiencia clinica mexicana. Rev Gastroenterol Mex 1998; 63: 11-16.
9. Corinaldesi R, Valentini M, Belaiche J, Colin R, Geldof H, Maier C, and the European Pantoprazole Study Group. Pantoprazole and omeprazole in the treatment of reflux oesophagitis: A European multicentre study. Aliment Pharmacol Ther 1995; 9: 667-671.
10. Dupas J-L, Houcke P, Giret-d’Orsay G, Samoyeau R. First comparison pantoprazole versus lansoprazole in hospital and private practice patients with reflux oesophagitis. DDW 1998; A: 3861
11. Hotz J, Brandstaetter G, Fumagalli I. Comparison of pantoprazole and omeprazole in acute reflux esophagitis. Gut 1996; 39: 220
12. Moessner J, Hoelscher AH, Herz R, Schneider A. A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: A multicentre trial. Aliment Pharmacol Ther 1995; 9: 321-326.
13. Vicari F, Belin J, Marek L. Pantoprazole 40 mg versus omeprazole 20 mg in the treatment of reflux oesophagitis: Results of a French multicentric double-blind comparative trial. Gastroenterology 1998; 114: A1324
14. Arnold A. Safety of proton pump inhibitors-and overview. Aliment Pharmacol Ther 1994; 8 (suppl 1): 65-70.
15. Hahn EG, Scholten T. Efficacy and tolerability of pantoprazole versus ranitidine and famotidine in patients with acute duodenal ulcers: multicenter, open randomized, controlled studies. Intern Clin Pract 1997; 5: 13-18.
16. Verdu EF, Armstrong D, Fraser R, Viani F, Idstrom J-P, Cederberg C. et al. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut 1995; 36: 539-543.
17. Labenz J, Tillenburg B, Peitz U, Idstrom J-P, Verdu E, Stolte M. et al. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology 1996; 110: 725-732.
18. Kuipers EJ, Bloemena E, Hazenberg HJA, Lindeman J, Klinkenberg-Knol EC, Meuwissen SGM. Changes in Helicobacter pylori-associated gastritis during acid suppressive therapy. Gastroenterology 1994; 106: A112
19. Lundell L, Havu N, Andersson A, Miettinen P, Myrvoid HE, Pedersen SA. et al. Gastritis development and acid suppression therapy revisited: Results of a randomised clinical study with long-term follow-up. Gastroenterology 1997; 112: A28
20. Adamek RJ, Bethke TD. Cure of Helicobacter pylori infection and healing of duodenal ulcer: Comparison of pantoprazole-based one-week modified triple therapy versus two-week dual therapy. Am J Gastroenterol 1998; 93: 1919-1924.
21. Holtmann G, Cain A, Malfertheimer P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 1999; 117: 11-16.